

09/743682
522 Rec'd PCT/PTO 10 JAN 2001

Practitioner's Docket No. 586.02-US1

PATENT

Preliminary Classification:

Proposed Class:

Subclass:

**TRANSMITTAL LETTER TO THE U.S. DESIGNATED OFFICE (DO/US)--
ENTRY INTO THE U.S. NATIONAL STAGE UNDER CHAPTER I**

PCT/IB00/00673	19 May 2000 (19.05.00)	20 May 1999 (20.05.99)
International Application Number	International Filing Date	International Earliest Priority Date

TITLE OF INVENTION: DIFFERENTIALLY EXPRESSED GENES IN PROSTATE CANCER

APPLICANT(S) FOR DO/US: SAATCIOGLU, Fahri


Box PCT
Assistant Commissioner for Patents
Washington D.C. 20231
ATTENTION: DO/US

CERTIFICATION UNDER 37 C.F.R. section 1.10*

(Express Mail label number is **mandatory**.)

(Express Mail certification is **optional**.)

I hereby certify that this paper, along with any document referred to, is being deposited with the United States Postal Service on this date **January 10, 2001**, in an envelope as "Express Mail Post Office to Addressee," mailing Label Number **EL733694043US**, addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.



Kristin J. Azezna

WARNING: Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. section 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b).

"Since the filing of correspondence under [section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

09/743682
500 Rec'd PCT/PTO 10 JAN 2001

1. Applicant herewith submits to the United States Designated Office (DO/US) the following items under 35 U.S.C. section 371:

This express request to immediately begin national examination procedures (35 U.S.C. section 371(f)). The U.S. National Fee (U.S.C. section 371(c)(1)), as indicated below:

2. Fees

CLAIMS FEE*	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS	36 -20 =	16	x \$18.00 =	\$288.00
	INDEPENDENT CLAIMS	13 - 3 =	10	x \$80.00 =	\$800.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$270					\$0.00
BASIC FEE					\$860.00
The international search fee, as set forth in Section 1.445(a)(2) to be paid to the US PTO acting as an international Searching Authority: where a search report on the international application has been prepared by the European Patent Office or the Japanese Patent Office (37 CFR 1.492(a)(5))\$860.00					
Total of above Calculations					= \$1,948.00
Reduction by 1/2 for filing by small entity, if applicable. Affidavit must be filed (note 37 CFR 1.9, 1.27, 1.28).					- \$974.00
Subtotal					\$974.00
Total National Fee					\$974.00
Fee for recording the enclosed assignment document \$40.00 (37 CFR 1.21(h)). (See Item below). See attached "ASSIGNMENT COVER SHEET".					\$0.00
TOTAL	Total Fees enclosed				\$974.00

A check in the amount of \$974.00 to cover the above fees is enclosed.

3. A copy of the International application as filed (35 U.S.C. section 371(c)(2)) is transmitted herewith.

4. A translation of the International application into the English language (35 U.S.C. section 371(c)(2)) is not required as the application was filed in English.

5. Amendments to the claims of the International application under PCT Article 19 (35 U.S.C. section 371(c)(3)) are transmitted herewith.

09/743682
500 Rec'd PCT/PTO 10 JAN 2001

6. An oath or declaration, including power of attorney, of the inventor (35 U.S.C. section 371(c)(4)) complying with 35 U.S.C. section 115 is submitted herewith, and such oath or declaration is attached to application.

II. Other document(s) or information included:

7. An international Search Report or Declaration under PCT Article 17(2)(a) will be transmitted promptly upon request.

8. An Information Disclosure Statement under 37 C.F.R. sections 1.97 and 1.98 will be transmitted within THREE MONTHS of the date of submission of requirements under 35 U.S.C. § 371(c).

9. Additional documents:

Copy of request (PCT/RO/101)
International Publication No. WO00/71700
Specification, claims and drawing
Preliminary amendment (37 C.F.R. section 1.121)

10. The above checked items are being transmitted after publication and the article 20 communication, but before 20 months from the priority date.

AUTHORIZATION TO CHARGE ADDITIONAL FEES

The Commissioner is hereby authorized to charge the following additional fees that may be required by this paper and during the entire pendency of this application to Account No. 500341.

37 C.F.R. section 1.492(a)(1), (2), (3), and (4) (filing fees)
37 C.F.R. section 1.492(b), (c), and (d) (presentation of extra claims)
37 C.F.R. section 1.17 (application processing fees)
37 C.F.R. section 1.17(a)(1)-(5) (extension fees pursuant to section 1.136(a))

Date: January 10, 2001



Robert D. Fish
Fish & Associates, LLP
1440 N. Harbor Blvd.
Suite 706
Fullerton, CA 92835
USA

Practitioner Docket No. 586.02-US1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231**

Inventor: **Fahri Saatcioglu**

Serial No: **U.S. National Phase
Application of PCT/IB00/00673**

Filed: **May 19, 2000**

For: **Differentially Expressed
Genes in Prostate Cancer**

Examiner: **Not Yet Assigned**

Art Unit: **Not Yet Assigned**

PRELIMINARY AMENDMENT

The Honorable Commissioner
of Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

Please enter the following preliminary amendment:

IN THE CLAIMS

5. (Amended) The polynucleotide of [any one of] claim 1[, 3, or 4] wherein the polynucleotide is expressed *in vivo* in a prostate cancer cell.
6. (Amended) The polynucleotide of [any one of] claim 1[, 3, or 4] wherein the expression of the polynucleotide is dependent on at least one of an androgen, a progesterone, an estrogen, and a glucocorticoid.
33. (Added) The polynucleotide of claim 3 wherein the polynucleotide is expressed *in vivo* in a prostate cancer cell.
34. (Added) The polynucleotide of claim 4 wherein the polynucleotide is expressed *in vivo* in a prostate cancer cell.

35. (Added) The polynucleotide of claim 3 wherein the expression of the polynucleotide is dependent on at least one of an androgen, a progesterone, an estrogen, and a glucocorticoid.

36. (Added) The polynucleotide of claim 4 wherein the expression of the polynucleotide is dependent on at least one of an androgen, a progesterone, an estrogen, and a glucocorticoid.

REMARKS

The foregoing amendments simply eliminate the multiple dependency of claims 5 and 6. No new matter has been added.

REQUEST FOR ALLOWANCE

Claims 1-36 are pending in this application. The applicants request allowance of all pending claims.

Respectfully submitted,

Fish & Associates, LLP

By: 

Robert D. Fish
Reg. No. 33,880

Dated: January 19, 2001

Attorneys for Applicant(s)
1440 N. Harbor Blvd., Suite 706
Fullerton, CA 92835
Tel.: (714) 449-2337
Fax: (714) 449-2339

Wprts

- 1 -

DIFFERENTIALLY EXPRESSED GENES IN PROSTATE CANCER

This application claims the benefit of U.S. provisional application number 60/135,325 filed May 20, 1999, and U.S. provisional application number 60/135,333 filed May 20, 1999, both of which are incorporated herein by reference in their entirety.

5 Field of The Invention

The field of the invention is neoplastic diseases, and especially detection and therapy of prostate cancer.

Background of The Invention

Prostate cancer has become the most commonly diagnosed malignancy in males in the western world, and is the second most common cause of cancer death among men in Europe and the United States (Boring, C.C., Squires, T.S., and Tong, T. (1993). *Cancer J. Clin.* 43, 7-26; Carter, H.B., Pianpadosi, S., and Isaacs, J.T. (1990). *J. Urol.* 143, 742-746). Worse yet, in recent years the annual incidence rate of newly diagnosed prostate cancer, as well as the number of prostate cancer deaths continuously rose.

Androgens not only play a key role in the development and maintenance of the normal prostate, but also in the initiation and progression of prostate cancer (Moore, R.A. (1944).

Surgery 16, 152-167; Huggins, C., and Johnson, M.A. (1947). *J. Am. Med. Assoc.* 135, 1146-1152). For example, androgens typically induce cell proliferation and inhibit cell death in the healthy prostate gland. Withdrawal of androgens stops proliferation of cells and induces apoptosis with concomitant involution of the prostate gland. Involution upon androgen withdrawal is generally a characteristic of a normal prostate gland as well as of a prostate tumor in the early stages of the disease, when the tumor still remains androgen dependent. Consequently, androgen withdrawal treatment is commonly used to reverse tumor growth. However, in the case of many prostate tumors, the tumor recurs after a few months or years almost invariably in an androgen insensitive state. At this point, successful therapy of prostate cancer is difficult and prognosis for survival is usually relatively low.

Almost all of the biological effects of androgens are mediated by the androgen receptor, a hormone-activated transcription factor. Even though the androgen receptor was cloned over ten years ago, the mechanisms by which the androgen receptor regulates gene expression is not well-

understood. Furthermore, only a very few of its target genes have been identified, including the prostate specific antigen (PSA), the related glandular kallikrein 2 (hKLK2), and the androgen receptor itself. Another androgen regulated protein, a secreted serine protease with prostate restricted expression, termed "prostase" was recently described by Nelson et al. (Nelson, P.S., et al. (1999) *Proc. Natl. Acad. Sci.* 96, 3114-3119). However, the biological functions of the proteins coded by the PSA, hKLK2 and prostase genes are poorly understood at present.

10
11
12
13
14
15

Adding to the difficulties in understanding the role of androgens in prostate cancer is that *in vivo* and *in vitro* model systems frequently do not closely mimic the human disease. Furthermore, close homologues of the PSA gene, the only marker for prostate cancer in human, are not known in other animal species. Moreover, *in vitro* studies are hampered due to the limited number of cell lines that have been derived from human prostate. For example, the only androgen sensitive and androgen responsive cell line that is widely used is LNCaP, characterized by cells originally derived from a lymph node metastasis of a human prostate carcinoma (Horoszewicz, J.S., Leong, S.S., Kawinski, E., Karr, J.P., Rosenthal, H., Chu, T.M., Mirand, E.A., and Murphy, G.P. (1983). *Cancer Res.* 43, 1809-1818).

20

In spite of numerous studies on the effects of androgens in the role of prostate cancer, relatively little is known about the molecular genetic effects of androgens in prostate cells. More detailed knowledge about androgen responsive genes and their role in signal transduction, as well as gross morphological and physiological transformations will potentially result in better diagnostic tools, and provide possible new targets for a drug-based therapy of prostate cancer. Therefore, there is still a need to provide improved methods to identify androgen responsive, differentially expressed genes in prostate cancer.

Summary of the Invention

The present invention is directed to differentially expressed genes in neoplastic cells, and particularly relates to hormone dependent genes in prostate cancer. The polynucleotides with the SEQ ID NO:1 - SEQ ID NO:7 encode an intracellular protein, and while the corresponding polypeptides SEQ ID NO:11 - SEQ ID NO:14 have an intracellular location, the corresponding expression products SEQ ID NO:8 - SEQ ID NO:10 have predominantly perinuclear, nuclear and predominantly nuclear localization within a cell, respectively.

In one aspect of the inventive subject matter, SEQ ID NO:1 - SEQ ID NO:7 are expressed in prostate cancer cells in a hormone dependent manner.

In another aspect of the inventive subject matter, a method of detecting a neoplastic cell in a system includes a step in which a predetermined amount of an RNA comprising at least one of SEQ ID NO:15 - SEQ ID NO:21 is correlated with the presence of a neoplastic cell, and the predetermined amount, or more, is subsequently detected in the system. Contemplated detection methods preferably employ a labeled probe that is detectable via fluorescence detection, luminescence detection, scintigraphy, autoradiography, or formation of a dye. Alternative preferred detection methods include addition of at least one nucleotide to the probe (e.g., PCR, 5 LCR).

In a further aspect of the inventive subject matter, a method of detecting a neoplastic cell in a system includes a step in which a predetermined amount of a polypeptide comprising at least one of SEQ ID NO:8 - SEQ ID NO:14 is correlated with the presence of a neoplastic cell, and the predetermined amount, or more, is subsequently detected in the system. Contemplated detection methods preferably employ a labeled probe that is detectable via fluorescence detection, luminescence detection, scintigraphy, autoradiography, or formation of a dye, and preferred probes include antibodies, antibody fragments, and natural and synthetic ligands of the polypeptide. 10 15

In a still further aspect of the inventive subject matter, a method of identifying differentially expressed genes in a target tissue has one step in which a target tissue-specific cDNA library 20 is prepared by suppression subtractive hybridization, and a plurality of genes from the library is immobilized on a solid phase. Nucleic acid preparations from treated and untreated target tissue are individually hybridized with array, respectively, and hybridization patterns are compared to identify differentially expressed genes.

25 Various objects, features, aspects and advantages of the present invention will become more apparent from the following detailed description of preferred embodiments of the invention, along with the accompanying drawing.

Brief Description of The Drawing

Figures 1A and 1B depict schematic nucleic acid and amino acid based multiple sequence alignments of SEQ ID NO:1 - SEQ ID NO:7 and SEQ ID NO:8 - SEQ ID NO:13, respectively.

5 Figure 2 is a photograph of an exemplary reverse northern blot of several clones from a cDNA library of androgen treated prostate cancer cells.

10 Figure 3 is a photograph of an exemplary multiple tissue northern blot of one of the isolated polynucleotides.

15 Figure 4 is a photograph of an agarose gel after electrophoretic separation of splicing variants of SEQ ID NO:1.

Figure 5 is a series of photomicrographs illustrating the intracellular localization of GFP-fusion proteins of polypeptides of SEQ ID NO:8 - SEQ ID NO:10.

20 Figure 6 is an autoradiograph of a northern blot indicating hormone dependent expression of SEQ ID NO:1 - SEQ ID NO:7.

Detailed Description

25 As used herein, the term "intracellular protein" refers to a protein that is expressed and retained within a cell irrespective of its subcellular localization. For example, DNA polymerase (nucleus), glyceraldehyde-3-phosphate dehydrogenase (cytoplasm), and cytochrome c oxidase (mitochondria) are all considered intracellular proteins. In contrast, the term "extracellular protein" refers to a protein that is exported from a cell. There are various mechanisms by which a protein can be exported from a cell, all of which are contemplated herein. For example, while many exported proteins have a signal sequence that allows specific export of the protein across a cell membrane, other proteins are exported through vesicles via the endoplasmatic reticulum, etc.

As also used herein, a protein has a "predominantly perinuclear localization" when a 25 majority of the protein (*i.e.*, more than 50% of the total amount as fluorimetrically detectable by GFP-fusion) is located in a volume around the nucleus that does not exceed a volume greater than three volumes of the nucleus. A protein has a "predominantly nuclear localization" when a majority of the protein is located within the nucleus. In contrast, the term "nuclear localization"

means that substantially all of the detectable protein is located within the nucleus. Localization of a protein can be determined fluorimetrically by GFP-fusion (GFP: green fluorescence protein).

Employing a novel combined SSH-reverse northern blot procedure (first disclosed in 5 provisional application 60/135,325 filed May 20, 1999), we isolated seven cDNAs (SEQ ID NO:1 - SEQ ID NO:7) from human prostate cancer cells. All seven cDNA molecules code for an intracellular protein, which is expressed in an androgen and glucocorticoid dependent manner. Remarkably, the sequences SEQ ID NO:1 - SEQ ID NO:7 show a high degree of homology/identity with prostase, a previously reported serine protease (Nelson, P.S., et al. 10 (1999) *Proc. Natl. Acad. Sci.* 96, 3114-3119). However, in comparison with the prostase, all of the sequences SEQ ID NO:1 - SEQ ID NO:7 lack a 49 amino acid N-terminal portion corresponding to the first exon of the prostase. It should be especially appreciated that the first exon of the prostase not only includes structurally important amino acids, but also includes a signal peptide sequence that renders the serine protease a secreted, extracellular enzyme. Consequently, the cDNA molecules with the sequence of SEQ ID NO:1 - SEQ ID NO:7 encode intracellular proteins that are functionally and structurally different from the prostase, and are therefore independent and novel genes.

15
16
17
18
19
20
21
22
23
24
25

With respect to the base composition of SEQ ID NO:1 - SEQ ID NO:7, nucleotide sequences other than SEQ ID NO:1 - SEQ ID NO:7 are also contemplated and particularly include 20 variations of SEQ ID NO:1 - SEQ ID NO:7 that include point mutations, insertions, deletions and any reasonable combination thereof, so long as alternative sequences encode an intracellular protein. Therefore, polynucleotides are contemplated that have at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% identity with the sequences of SEQ ID NO:1 - SEQ ID NO:7, so long as contemplated polynucleotides encode an intracellular 25 protein.

For example, point mutations may arise at any position of the sequence from an apurinic, 30 apyrimidinic, or otherwise structurally impaired site within the cDNA. Alternatively, point mutations may be introduced by random or site-directed mutagenesis procedures (e.g., oligonucleotide assisted or by error prone PCR). Likewise, deletions and/or insertions may be introduced into the sequences, and particularly preferred insertions comprise 5'- and/or 3'-fusions with a polynucleotide that encodes a reporter moiety or an affinity moiety. Other particularly

preferred insertions comprise a nucleic acid that further includes functional elements such as a promoter, enhancer, hormone responsive element, origin of replication, transcription and translation initiation sites, etc. It should especially be appreciated that where insertions with one or more functional elements are present, the resulting nucleic acid may be linear or circular (e.g., 5 transcription or expression cassettes, plasmids, etc.).

10 15 20 25 30

Still further contemplated variations include substitution of one or more atoms or chemical groups in the sequence with a radioactive atom or group. For example, where contemplated cDNAs are employed as a hybridization-specific probes, a fluorophor or enzyme (e.g., β -galactosidase for generation of a dye, or luciferase for generation of luminescence) may be coupled to the sequence to identify position and/or quantity of a complementary sequence. Alternatively, where contemplated cDNA molecules are utilized for affinity isolation procedures, the cDNA may be coupled to a molecule that is known to have a high-affinity (i.e., $K_d < 10^4 \text{ mol}^{-1}$) partner, such as biotin, or an oligo-histidyl tag. In another example, one or more phosphate groups may be exchanged for a radioactive phosphate group with a ^{32}P or ^{33}P isotope to assist in detection and quantification, where the radiolabeled cDNA is employed as a hybridization probe.

10 15 20 25 30

It is also contemplated that the polypeptides (encoded by SEQ ID NO:1 – SEQ ID NO:7) having the peptide sequence of SEQ ID NO:8 – SEQ ID NO:14 may be produced *in vivo* or *in vitro*, and may be chemically and/or enzymatically modified. Contemplated polypeptides can be isolated from prostate tissue or prostate cancer cells that may or may not be in a hormone dependent state. Alternatively, and especially where larger amounts (i.e., >10mg) are desirable, recombinant production (e.g., in a bacterial, yeast, insect cell, or mammalian cell system) may advantageously be employed to generate significant quantities of contemplated polypeptides.

It should further be appreciated that recombinant production not only offers a more economical strategy to produce contemplated polypeptides, but also allows specific modification in the amino acid sequence and composition to tailor particular biochemical, catalytic and physical properties. For example, where increased solubility of contemplated polypeptides is desirable, one or more hydrophobic amino acids may be replaced with hydrophilic amino acids. Alternatively, where reduced or increased catalytic activity is required, one or more amino acids may be replaced or eliminated. In still another example, fusion proteins with contemplated proteins are contemplated, in which an additional polypeptide is added to the N-terminus and/or C-terminus

of contemplated polypeptide. Particularly contemplated fusion proteins include fusions with enzymatically active fusion partners (*e.g.*, for dye formation or substrate conversion) and fluorescent fusion partners such as GFP, EGFP, BFP, etc. Therefore, sequences other than the sequences of SEQ ID NO:8 – SEQ ID NO:14 are also contemplated, so long as the polypeptides are 5 intracellular proteins, and alternative peptide sequences may have a sequence that has a 70%, preferably 80%, more preferably 90%, and most preferably 95% homology to the sequences of SEQ ID NO:8 – SEQ ID NO:14.

With respect to chemical and enzymatic modifications of contemplated polypeptides, it is contemplated that many modifications are appropriate, including addition of mono-, and bifunctional linkers, coupling with protein- and non-protein macromolecules, and glycosylation. For example, mono- and bifunctional linkers are especially advantageous where contemplated polypeptides are immobilized to a solid support, or covalently coupled to a molecule that enhances immunogenicity of contemplated polypeptides (*e.g.*, KLH, or BSA conjugation). Alternatively, contemplated polypeptides may be coupled to antibodies or antibody fragments to allow rapid retrieval of the polypeptide from a mixture of molecules. Further contemplated couplings include covalent and non-covalent coupling of contemplated polypeptides with molecules that prolong the serum half-life and/or reduce immunogenicity such as cyclodextranes and polyethylene glycols.

In a particularly contemplated aspect of the inventive subject matter, SEQ ID NO: 15 – 20 SEQ ID NO:21 (the corresponding mRNA of SEQ ID NO: 1 – SEQ ID NO:7) are employed in a method of detecting a neoplastic cell in a system. In one step, a predetermined quantity of an RNA comprising at least one of SEQ ID NO:15 - SEQ ID NO:21 in a cell containing system is correlated with the presence of a neoplastic cell, wherein the RNA encodes an intracellular polypeptide, and in a further step, an amount of at least the predetermined quantity of the RNA is 25 detected in the system.

In a preferred embodiment, the system is a mammal (most preferably a human) and the neoplastic cell is a prostate cancer cell in a biopsy specimen. The total RNA is extracted from the biopsy specimen, and a real time quantitative rt-PCR employing individual reactions with primer pairs specific to each of the sequences of SEQ ID NO:15 - SEQ ID NO:21 is performed in 30 parallel with a biopsy specimen known to be free of cancer cells. Biopsy specimens are determined to have a cancer cell, where the detected mRNA quantity of SEQ ID NO:15 - SEQ ID

NO:21 is at least 3 times higher than in the control specimen. A preferred extraction of total RNA utilizes the Quiagen BioRobot kit in conjunction with the BioRobot 9600 system, and the real time rtPCR is performed in a Perkin Elmer ABI Prism 7700.

In alternative aspects of the inventive subject matter, the method of detecting a neoplastic cell need not be limited to biopsy tissues from prostate tissue, but may employ various alternative tissues, including lymphoma tumor cells, and various solid tumor cells, so long as such tumor cells overproduce mRNA of the SEQ ID NO:15 - SEQ ID NO:21. Appropriate alternative tumor cells can readily be identified by the above described method. Likewise, the system need not be restricted to a mammal, but may also include cell-, and tissue cultures grown *in vitro*, and tumor cells and specimens from animals other than mammals.

10

For example, tumor cell and tissue grown *in vitro* may advantageously be utilized to investigate drug action on such cells, and the overabundance of sequences of SEQ ID NO:15 - SEQ ID NO:21 may conveniently be employed as tumor marker. Alternatively, body fluids (e.g., serum, saliva, etc.) that may or may not contain tumor cells are also contemplated a suitable substrate for the method presented herein, so long as they contain to at least some extent mRNA with a sequence of SEQ ID NO:15 - SEQ ID NO:21.

15

20

25

30

35

40

45

50

55

60

65

70

75

80

85

90

95

100

105

110

115

120

125

130

135

140

145

150

155

160

165

170

175

180

185

190

195

200

205

210

215

220

225

230

235

240

245

250

255

260

265

270

275

280

285

290

295

300

305

310

315

320

325

330

335

340

345

350

355

360

365

370

375

380

385

390

395

400

405

410

415

420

425

430

435

440

445

450

455

460

465

470

475

480

485

490

495

500

505

510

515

520

525

530

535

540

545

550

555

560

565

570

575

580

585

590

595

600

605

610

615

620

625

630

635

640

645

650

655

660

665

670

675

680

685

690

695

700

705

710

715

720

725

730

735

740

745

750

755

760

765

770

775

780

785

790

795

800

805

810

815

820

825

830

835

840

845

850

855

860

865

870

875

880

885

890

895

900

905

910

915

920

925

930

935

940

945

950

955

960

965

970

975

980

985

990

995

1000

1005

1010

1015

1020

1025

1030

1035

1040

1045

1050

1055

1060

1065

1070

1075

1080

1085

1090

1095

1100

1105

1110

1115

1120

1125

1130

1135

1140

1145

1150

1155

1160

1165

1170

1175

1180

1185

1190

1195

1200

1205

1210

1215

1220

1225

1230

1235

1240

1245

1250

1255

1260

1265

1270

1275

1280

1285

1290

1295

1300

1305

1310

1315

1320

1325

1330

1335

1340

1345

1350

1355

1360

1365

1370

1375

1380

1385

1390

1395

1400

1405

1410

1415

1420

1425

1430

1435

1440

1445

1450

1455

1460

1465

1470

1475

1480

1485

1490

1495

1500

1505

1510

1515

1520

1525

1530

1535

1540

1545

1550

1555

1560

1565

1570

1575

1580

1585

1590

1595

1600

1605

1610

1615

1620

1625

1630

1635

1640

1645

1650

1655

1660

1665

1670

1675

1680

1685

one nucleotide to the probe, and especially contemplated enzymatic additions include LCR and PCR.

In still other aspects of contemplated methods, the mRNA quantity need not necessarily be limited to at least 3 times more than in the control specimen in order to establish that the 5 tissue has a cancer cell. For example, where the concentration of mRNA is hormone dependent, higher amounts between 3-8 fold and more may be appropriate. In contrast, where the concentration of cancer cells in the biopsy specimen is relatively low, amounts of less than 3-fold, including 1.5 to 2.9-fold and less are contemplated.

In another particularly contemplated aspect of the inventive subject matter, polypeptide 10 of SEQ ID NO: 8 – SEQ ID NO:14 (encoded by SEQ ID NO: 1 – SEQ ID NO:7) are employed in a method of detecting a neoplastic cell in a system. In one step, a predetermined quantity of an intracellular polypeptide comprising at least one of SEQ ID NO:8 - SEQ ID NO:14 in a cell containing system is correlated with the presence of a neoplastic cell, and in a further step, an amount of at least the predetermined quantity of the RNA is then detected in the system.

In a preferred embodiment, the system is a mammal (most preferably a human) and the 15 neoplastic cell is a prostate cancer cell or a breast cancer cell in a biopsy specimen. The biopsy specimen that is suspected to have a cancer cell is flash frozen, dissected on a microtome, and sections are mounted on microscope slides. The sections are subsequently incubated with a fluorescein labeled antibody that is directed against an epitope of at least one of the polypeptides 20 of SEQ ID NO:8 - SEQ ID NO:14. Fluorescence is detected with a fluorescence microscope coupled to a CCD-video camera and image analysis equipment. Biopsy specimens are determined to have a cancer cell, where the fluorescence signal/quantity of one or more cells is at least 3 times higher than in the control specimen.

In alternative aspects of the inventive subject matter, the method of detecting a neoplastic 25 cell need not be limited to biopsy tissues from prostate tissue, but may employ various alternative tissues, including lymphoma tumor cells, and various solid tumor cells, so long as such tumor cells overproduce polypeptides of the SEQ ID NO:8 - SEQ ID NO:14. Appropriate alternative tumor cells can readily be identified by the above described method. Likewise, the system need not be restricted to a mammal, but may also include cell, and tissue cultures grown *in vitro*, 30 and tumor cells and specimens from animals other than mammals. For example, tumor cell and

tissue grown *in vitro* may advantageously be utilized to investigate drug action on such cells, and the polypeptides of SEQ ID NO:8 - SEQ ID NO:14 may conveniently be employed as a tumor marker. Alternatively, body fluids (e.g., serum, saliva, etc.) that may or may not contain tumor cells are also contemplated as suitable substrates for the method presented herein, so long as they 5 contain to at least some extent the polypeptides of SEQ ID NO:8 - SEQ ID NO:14.

With respect to detection methods, it is contemplated that many methods other than fluorescence microscopy are also appropriate, and particularly contemplated methods include specific binding of a probe to at least one of SEQ ID NO:8 - SEQ ID NO:14. It is especially contemplated that suitable probes are labeled, and depending on the physico-chemical nature of 10 the probe, the detection process may include fluorescence detection, luminescence detection, scintigraphy, autoradiography, and formation of a dye.

For example, for microscopic analysis of biopsy specimens, luciferase labeled probes are particularly advantageous in conjunction with a luminescence substrate (e.g., luciferin). Luminescence quantification may then be performed utilizing a CCD-camera and image analysis system. Similarly, radioactivity may be detected via autoradiographic or scintigraphic procedures on 15 a tissue section, in a fluid or on a solid support. Where the probe is a natural or synthetic ligand of contemplated polypeptides, particularly contemplated ligands include molecules with a chemical modification that increase the affinity to the polypeptide and/or induce irreversible binding to the polypeptide. For example, transition state analogs or suicide inhibitors for a 20 particular reaction catalyzed by the polypeptide are especially contemplated. Labeling of antibodies, antibody fragments, small molecules, and binding of the labeled entity is a technique that is well known in the art, and it is contemplated that all known methods are generally suitable for use in conjunction with methods contemplated herein. Furthermore, the probe need not be limited to a fluorescein labeled antibody, and alternative probes include antibody fragments (e.g., 25 Fab, Fab', scFab, etc.).

In still other aspects of contemplated methods, the polypeptide quantity need not necessarily be limited to at least 3 times more than the control specimen in order to establish that the tissue has a cancer cell (e.g., where the control reads 100ng, three times more than the control means 300ng). For example, where the concentration of the polypeptide is hormone dependent, 30 higher amounts between 3-8 fold and more may be appropriate. In contrast, where the concen-

tration of cancer cells in the biopsy specimen is relatively low, amounts of less than 3-fold, including 1.5 to 2.9-fold and less are contemplated.

It should further be appreciated that the polynucleotides of SEQ ID NO:1- SEQ ID NO:7 and SEQ ID NO:15 - SEQ ID NO:21 may be employed as a therapeutic modality in an antisense DNA/RNA based therapy. Anti-sense therapy, for example, could be employed to inhibit, up-, or down-regulate transcription or translation of the genes corresponding to SEQ ID NO:1- SEQ ID NO:7. It should further be appreciated that an anti-sense approach may also include regulatory sequences associated with SEQ ID NO:1- SEQ ID NO:7 such as transcription enhancers, hormone responsive elements, ribosomal- and RNA polymerase binding sites, etc., which may be located upstream or downstream of SEQ ID NO:1- SEQ ID NO:7, and may have a distance of several ten base pairs to several ten thousand base pairs.

Alternatively, the polypeptides of SEQ ID NO:8- SEQ ID NO:14 may also be employed in an antibody based therapy or a small molecule drug therapy directed towards the polypeptides of SEQ ID NO:8- SEQ ID NO:14. For example, antibody based therapy could be employed to neutralize, or remove corresponding polypeptides of SEQ ID NO:8- SEQ ID NO:14 *in-vivo*, or to interfere with one or more cellular functions of contemplated polypeptides.

Figures 1A and 1B show a schematic and an amino acid based alignment between the cDNAs of SEQ ID NO:1 - SEQ ID NO:7, in which SEQ ID NO:1 is the full-length cDNA and SEQ ID NO:2 - SEQ ID NO:7 are splicing variants of SEQ ID NO:1. In the amino acid based alignment SEQ ID NO:8 is the corresponding polypeptide to SEQ ID NO:1, and SEQ ID NO:9 - SEQ ID NO:14 are the corresponding polypeptides to SEQ ID NO:2 - SEQ ID NO:6.

Examples

The following examples illustrate the isolation and cloning of the sequences of SEQ ID NO:1 - SEQ ID NO:7 from normal prostate tissue and from prostate cancer cells. SEQ ID NO:8 - SEQ ID NO:14, and SEQ ID NO15 - SEQ ID NO:21 are computer generated transcriptions and translations of SEQ ID NO1 - SEQ ID NO:7, respectively.

The following examples also illustrate a general method of identifying differentially expressed genes in a target tissue, in which in one step a target tissue-specific cDNA library is provided that has a plurality of tissue-specific genes obtained by suppression subtractive

hybridization. In a subsequent step, a predetermined quantity of tissue-specific genes is immobilized on a solid phase to form a tissue-specific cDNA array, and a first nucleic acid preparation is hybridized to a first tissue-specific cDNA array to create a first hybridization pattern, wherein the first preparation is prepared from the target tissue without previously 5 exposing the target tissue to a compound. In a further step, a second nucleic acid preparation is hybridized to a second tissue-specific cDNA array to create a second hybridization pattern, wherein the second preparation is prepared from the target tissue after previously exposing the target tissue to a compound. In yet a further step, the first and the second hybridization pattern are then compared to identify differentially expressed genes. This general method is especially 10 contemplated where the compound comprises a hormone, or various other suitable ligands.

Suppression Subtraction of Prostate Specific Genes

cDNA derived from poly(A)+ RNA of 10 different normal human tissues were subtracted against normal human prostate cDNA using suppression subtraction hybridization (SSH) 15 (Diatchenko, L., Lau, Y.-F. C., Campbell, A.P., Chenchik, A., Moqadam, F., Huang, B., Lukyanov, S., Lukyanov, K., Gurskaya, N., Sverdlov, E.D., Siebert, P.D. (1996). *Proc. Natl. Acad. Sci. USA* 93, 6025-6030), and the resulting cDNA fragments were cloned into an appropriate vector. SSH was performed as described (Clontech PCR-Select Cloning Kit) using prostate 20 poly(A)+ RNA against a pool of poly(A)+ RNA obtained from ten normal human tissues (heart, brain, placenta, lung, liver, skeletal muscle, kidney, spleen, thymus, and ovary). Upon secondary PCR amplification (12 cycles), reactions were extracted with phenol/chloroform and DNA was precipitated with EtOH.

The pellet was washed once with 70% EtOH. After drying, the DNA pellet was dissolved in 0.2xTE or dH₂O and cut with RsaI in a 20 ul reaction for 2 hrs at 37C to excise adaptors. After 25 digestion, reactions were run on a 1.5 % agarose gel, with molecular size markers on one side, at 5 V/cm, 40 min. The adopter bands are excised and discarded, and cDNA bands were cut out and purified (QIAEX gel DNA purification kit) after running the gel backwards to concentrate the cDNA.

The purified DNA was subcloned into EcoRV-cut, dephosphorylated pZERO vector 30 from Invitrogen. DH10B electrocompetent cells (>10¹⁰ efficiency) were transformed with a 1/5 dilution of 1μl of the ligation mix.

Colonies were picked and the presence of cDNA inserts confirmed by PCR with T7 and SP6 primers directly from the colonies. 10% of reactions were run on a 1.5% agarose gel to visualize amplified products. The colonies with inserts were grown and glycerol stocks (15%) were prepared and stored at -80C.

5

Reverse Northern Blot and Sequence Analyses

Clones from the SSH library were amplified by PCR and spotted on nylon filters in 96-well format to generate two identical blots for each set of 92 clones (the remaining four spots were used for positive and negative controls). For probe preparation, the androgen-responsive prostate cancer cell line LNCaP (Horoszewicz, J.S., Leong, S.S., Kawinski, E., Karr, J.P., Rosenthal, H., Chu, T.M., Mirand, E.A., and Murphy, G.P. (1983). *Cancer Res.* 43, 1809-1818) was employed that was either untreated [the (-) probe] or treated with the synthetic androgen R1881 for 24 hours [the (+) probe]. Poly(A)+ RNA was isolated from these cells and was used to make the ³²P-labeled probes. After hybridization with the (-) and (+) probes, clones showing differential hybridization were selected for further analysis (*i.e.*, confirmation by a secondary reverse northern blot, and northern blotting).

Reverse northern screening on the cDNA clones were done essentially as described elsewhere (Hedrick, S.M., Cohen, D.I., Neilson, E.A., Davis, M.M. (1984) *Nature* 308, 149-153; Sakaguchi N, Berger CN, Melchers F (1986). *EMBO J* 5: 2139-2147). DNA (approximately 400 ng) from PCR amplification in step 6 was diluted in 200 µl of 0.4M NaOH, 10 mM EDTA and mixed well by pipetting. After incubation at 95°C for 5-10 min, the tubes were chilled on ice. Denatured DNA was blotted on two separate pieces of Zeta Probe GT+ membrane (Bio-Rad) using a dot-blot apparatus (Bio-Rad). Positive [Prostate specific antigen (PSA) cDNA] and negative [glyceraldehyde 3-phosphate dehydrogenase (G3PDH) cDNA] controls are included on each blot in duplicate. Membranes were rinsed with 2XSSC, air dried, and then baked at 80°C for 30 min. A typical example of a reverse northern analysis is shown in Figure 2. In each blot pair, PSA and G3PDH are included as positive and negative controls, respectively. It should be noted that there was substantial increase in PSA hybridization in the (+) blot (probe prepared from cells that have been stimulated by androgens) compared with the (-) blot (probe prepared from untreated cells), whereas there was no significant change in hybridization of G3PDH between the two blots. Arrowheads indicate differentially expressed clones.

As a control to verify the prostate specific nature of isolated sequences, positive clones were tested in a standard northern blot against RNA preparations of multiple non-prostate tissues and a typical blot is shown in **Figure 3**. Lanes 1-10, and 12-16 are RNA preparations from non-prostate tissues, lane 11 is a RNA preparation from prostate, lane 12 is a RNA preparation from 5 testis.

Probes: The probes were random-prime radiolabeled using standard laboratory procedures. Unincorporated nucleotides were removed using prespun G25 columns (Bio-Rad), and specific activity was typically over 5×10^8 cpm/ μ g.

Hybridization: 25 ml Hybridization mix (7% SDS, 0.5 M NaHPO₄, 1mM EDTA) at 65°C 10 is prewarmed, and 12.5 ml were used for prehybridization of each membrane for 5-10 min at 65 °C. Probes were heat denatured at 95°C for 3-5 min and transferred to the prehybridization mix at 65°C. Hybridization was done at 65°C overnight.

Washing: Wash solution I (2xSSC and 1% SDS) and wash solution II (0.1xSSC and 0.5% SDS) were prewarmed. Membranes were washed once with Solution I and then Solution II 15 for 30 min at 65°C, covered with plastic wrap and exposed to phosphorimager screen.

Selection: Clones showing differential expression between the (-) and (+) blots were 20 picked. A secondary round of reverse northern analysis is performed for confirmation by spotting each clone in duplicate on each blot. To confirm hormone dependence, a time course of R1881 induction of LNCaP cells as well as the CWR22 xenograft model upon androgen ablation (Wainstein, M. A., He, F., Robinson, D., Kung, H. J., Schwartz, S., Giaconia, J. M., Edgehouse, N. L., Pretlow, T. P., Bodner, D. R., Kursh, E. D., and Pretlow, T.G. (1994). *Cancer Res.* 54, 6049-6052) and the androgen-independent CWR22R relapsed xenograft (Nagabhushan, M., Miller, C. M., Pretlow, T. P., Giaconia, J. M., Edgehouse, N. L., Schwartz, S., Kung, H. J., de Vere White, R. W., Gumerlock, P. H., Resnick, M. I., Amini, S. B. , and Pretlow, T. G. (1996). *Cancer Res.* 56, 3042-6) was used.

Sequence analysis: Sequence analysis was performed by the dideoxy chain termination methods using an ABI automated sequencer. It should be appreciated that many more androgen responsive, differentially expressed genes can be identified and isolated using the cloning strategy outlined above, including genes expressed during various growth and developmental phases

of a diseased prostate, and genes expressed as a result of a drug regimen. Moreover, it is contemplated that not only differentially expressed prostate cancer genes can be identified and isolated, but also genes involved in other diseased states of human prostate, including benign prostate hyperplasia, etc.

5 **Isolation of Splice Variants (SEQ ID NO: 2 - SEQ ID NO: 7)**

Poly(A)⁺ RNA was isolated from LNCaP cells treated with R1881 (a synthetic androgen) and from androgen dependent prostate cancer xenograft CWR22 grown in nude mice in the presence of androgens. cDNA was prepared and subjected to PCR using SEQ ID NO:1 specific primers and a primer pair designed to amplify the previously published prostase. The respective 10 5'-primers were located around the translation start site, while the 3'-primer for all reactions was located around the stop codon. Reaction products were loaded onto an agarose gel and separated as shown in **Figure 4**. Lane 1 is a marker, lane 2 is positive control with SEQ ID NO:1 as template. Lanes 3-5 are PCR products from CWR22 cells with SEQ ID NO:1 specific primers, while lanes 6-8 are PCR products from CWR22 cells with prostase specific 5'-primer. Lanes 9-15 11 are PCR products from LNCaP cells with SEQ ID NO:1 specific primers, and lanes 12-14 are PCR products from LNCaP cells with prostase specific primers. Lane 15 is marker.

Only reactions with SEQ ID NO:1 specific primers yielded detectable PCR products, with a major band at 680bp (SEQ ID NO:1), and two additional bands at about 500bp (SEQ ID NO:2) and 750bp (SEQ ID NO:3). When primers for 5'-RACE analysis were employed, four 20 additional PCR products were obtained, corresponding to SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, respectively. All bands were sequenced to confirm their identity. SEQ ID NO:7 was obtained both as a 3'-RACE product as well as a distinct clone from the PSL library.

Localization of Intracellular Proteins encoded by SEQ ID NO: 1 - SEQ ID NO: 3

To gain insight into the subcellular location of the polypeptides SEQ ID NO:8 - SEQ ID 25 NO:10 (encoded by SEQ ID NO:1 - SEQ ID NO:3), C-terminal fusion constructs with GFP were produced in COS7 cells. The cells were fixed, stained with DAPI and visualized by phase contrast or fluorescence microscopy and representative images are shown in **Figure 5**. Photographs in lane A depict a GFP fusion protein with SEQ ID NO:9, the photographs in lane B depict a GFP fusion protein with SEQ ID NO:10, the photographs in lane C depict a GFP fusion protein 30 with SEQ ID NO:8, and the photographs in lane D depict a GFP protein as a control. The poly-

peptide of SEQ ID NO: 8 displayed strong granular fluorescence predominantly around the nucleus, while the polypeptide of SEQ ID NO:9 and SEQ ID NO:10 showed exclusively nuclear and predominantly nuclear localization, respectively. Due to the lack of an identifiable leader sequence that would indicate an export of the polypeptides of SEQ ID NO:11 - SEQ ID NO:14, 5 it is contemplated that the sequences SEQ ID NO:11 - SEQ ID NO:14 are also intracellular proteins.

Regulation of Expression by multiple Hormones

Untreated LNCaP cells and hormone treated LNCaP cells were employed to determine the hormone dependence of expression of SEQ ID NO:1. Treatment was as follows: Testosterone (T) at 10^{-8} M, dihydrotestosterone (DHT) at 10^{-8} M, estradiol (E2) at 10^{-8} M, progesterone (P) at 10^{-8} M, dexamethasone (Dex) at 10^{-7} M, 1, 25-dihydroxy-vitamin D3 (VitD3) at 10^{-8} M, and triiodothyronine (T3) at 10^{-7} M. The total RNA of the treated cells was isolated and used in a northern blot analysis with radiolabeled SEQ ID NO:1 as probe. Figure 6 shows the results of an autoradiograph of a northern blot as described above. 18S-RNA is shown as control for RNA integrity and loading. The relative induction of SEQ ID NO:1 is indicated at the bottom of the lanes as determined by phosphorimager analysis. It is contemplated that SEQ ID NO:2 - SEQ ID NO:7 are splice variants of SEQ ID NO:1, and consequently it is contemplated that the expression of all of SEQ ID NO:1 - SEQ ID NO:6 is hormone dependent, and particularly contemplated hormones include androgens, progesterones, estrogens and glucocorticoids.

20 Thus, specific embodiments and applications of methods and applications of differentially expressed genes in prostate cancer cells have been disclosed. It should be apparent, however, to those skilled in the art that many more modifications besides those already described are possible without departing from the inventive concepts herein. The inventive subject matter, therefore, is not to be restricted except in the spirit of the appended claims. Moreover, in 25 interpreting both the specification and the claims, all terms should be interpreted in the broadest possible manner consistent with the context. In particular, the terms "comprises" and "comprising" should be interpreted as referring to elements, components, or steps in a non-exclusive manner, indicating that the referenced elements, components, or steps may be present, or utilized, or combined with other elements, components, or steps that are not expressly 30 referenced.

-17-

SEQUENCE LISTING

SEQ ID NO:1

atggaaaacg aattgttctg ctggcggtc ctgggtgcac cgcagtggt gctgtcagcc 60
gcacactgtt tccagaactc ctacaccatc gggctggcc tgcacagtct tgaggccgac 120
caagagccag ggagccagat ggtggaggcc agcctctccg tacggcaccc agagtacaac 180
agacccttgc tcgctaacga cctcatgctc atcaagttgg acgaatccgt gtccgagtct 240
gacaccatcc ggagcatcag cattgcttcg cagtgcctta ccgcgggaa ctcttcctc 300
gtttctggct ggggtctgct ggcaacggc agaatgccta ccgtgctgca gtgcgtgaac 360
gtgtcgggtgg tgcgttgaggaa ggtctgcagt aagctctatg acccgctgtta ccaccccagc 420
atgttctgcg ccggcgagg gcaagaccag aaggactcct gcaacgggtga ctctgggggg 480
cccctgatct gcaacgggtta cttgcagggc cttgtgtctt tcggaaaagc cccgtgtggc 540
caagttggcg tgccaggtgt ctacaccaac ctctgcaaatt tcactgagtg gatagagaaaa 600
accgtccagg ccagttaa 618

SEQ ID NO:2

atggaaaacg aattgttctg ctggcggtc ctgggtgcac cgcagtggt gctgtcagcc 60
gcacactgtt tccagaactc ctacaccatc gggctggcc tgcacagtct tgaggccgac 120
caagagccag ggagccagat ggtggaggcc agcctctccg tacggcaccc agagtacaac 180
agacccttgc tcgctaacga cctcatgctc atcaagttgg acgaatccgt gtccgagtct 240
gacaccatcc ggagcatcag cattgcttcg cagtgcctta ccgcgggaa ctcttcctc 300
gtttctggct ggggtctgct ggcaacggg tgactctggg gggccctgta tctgcaacgg 360
gtacttgcag ggccttgtgt ctgtggaaa agcccccgtgt ggccaagttg gcgtgccagg 420
tgtctacacc aacctctgca aattcactga gtggatagag aaaaccgtcc aggccagtta 480
a 481

SEQ ID NO:3

atggaaaacg aattgttctg ctggcggtc ctgggtgcac cgcagtggt gctgtcagcc 60
gcacactgtt tccagaactc ctacaccatc gggctggcc tgcacagtct tgaggccgac 120
caagagccag ggagccagat ggtggaggcc agcctctccg tacggcaccc agagtacaac 180

agacccttgc tcgctaacga cctcatgctc atcaagttgg acgaatccgt gtccgagct 240
gacaccatcc ggagcatcag cattgcttcg cagtgcctta ccgcggggaa ctcttgctc 300
gtttctggct ggggtctgct ggcaacggt gagctcacgg gtgtgtgtct gccctcttca 360
aggaggtcct ctgcccagtc gcgggggctg acccagagct ctgcgtccca ggcagaatgc 420
ctaccgtgct gcagtgcgtg aacgtgtcgg tggtgtctga ggaggtctgc agtaagctct 480
atgaccggct gtaccacccc agcatgttct gcgcggcgg agggcaagac cagaaggact 540
cctgcaacgg tgactctggg ggggcctga tctgcaacgg gtacttgcat ggccttgtgt 600
ctttcggaaa agccccgtgt tggccaagtt ggcgtgccag gtgtctacac caacctctgc 660
aaattcactg aqgtggataqa qaaaaccgtc caqqccqgtt aa 702

SEQ ID NO:4

ggaatgagcc tggatccggg gagcccagag ggaagggctg ggaggcggga attttgcttc 60
ggaaggactc agagagtccct gacttgaat ctcagcccag tgctgagtct ctatgtaaact 120
aagctccctac accatcgccc tgggcctgca cagtcttgag gccgaccaag agccagggag 180
ccagatggtg gaggccagcc tctccgtacg gcacccagag tacaacagac ctttgctcgc 240
taacgaccc tcatgtccatca agttggacga atccgtgtcc gagtctgaca ccatccggag 300
catcagcatt gcttcgcagt gccctaccgc ggggaactct tgcctcgaaa ctggctgggg 360
tctgctggcg aacggtaaac tcacgggtgt gtgtctgccc tcttcaagga gatccctctgc 420
ccagtcgcgg gggctgaccc agagctctgc gtcccaggca gaatgcctac cgtgctgcag 480
tgcgtgaacg tgcgtgggt gtctgaggag gtctgcagta agctctatga cccgctgtac 540
cacccccagca tggatccgcgc cggcggaggg caagaccaga aggactcctg caacggtgac 600
tctggggggc ccctgatctg caacgggtac ttgcagggcc ttgtgtcttt cggaaaagcc 660
ccgtgtggcc aagttggcgt gccaggtgtc tacaccaacc tctgcaaatt cactgagtgg 720
atagagaaaa ccgtccaggg cagttaactc tggggactgg gaacccatga aattgacccc 780
caaatcacatc ctgcggaaagg aattcaggaa tatctgatcc cagccccctcc tccc 834

SEQ ID NO:5

ggaatgagcc tggatccggg gagcccagag ggaagggctg ggaggcggga atcttgcttc 60
ggaagggactc agagagccct qacttgaat ctcagccag tgctqagtct ctatgtaaact 120

-19-

aagctcctac accatcgggc tgggcctgca cagtctttag gcccaccaag agccagggag 180
ccagatggtg gagggcagcc tctccgtacg gcacccagag tacaacagac cttgctcgc 240
taacgaccc tc atgctcatca agttggacga atccgtgtcc gagtctgaca ccatccggag 300
catcagcatt gcttcgcagt gccctaccgc ggggaactct tgcctcgaaa ctggctgggg 360
tctgctggcg aacggcagaa tgcctaccgt gctgcagtgc gtgaacgtgt cggtggtgtc 420
tgaggaggtc tgca gtaa gtc 440

SEQ ID NO:6

ggctctggga ggaggacgga atgagcctgg atccggggag cccagagggaa agggctggga 60
ggcgggaatc ttgcttcgga aggactcaga gagccctgac ttgaaatctc agcccagtgc 120
tgagtctcta gtgaactaag ctcctacacc atcgggctgg gcctgcacag tcttgaggcc 180
gaccaagagc cagggagcca gatggggag gccagccctc ccgtacggca cccagagtac 240
aacagaccc tgc tgc gtaa cgc ac tca gtc tgg ac gaa atc cgt tcc gag 300
tctgacacca tccggagcat cagcatgtc tcgcagtgc ctaccgcggg gaa ctcttgc 360
ctcgttctg gctgggtct gctggcgaac ggcagaatgc ctaccgtgt gcagtgcgtg 420
aacgtgtcgg tgg tgc tctga ggagg tgc agtaa gtc 457

SEQ ID NO:7

accacccca gatgttctgc gccggcggag agcaagacca gaaggactcc tgcaacgtga 60
gagagggaa aggggagggc aggcaactca gggaaagggtg gagaaggggg agacagagac 120
acacagggcc gcatggcgag atgcagagat ggagagacac acagggagac agt gacaact 180
agagagagaa actgagagaa acagggaaat aaacacagga ataaagagaa gcaaaggaa 240
agagaaacag aaacagacat gggggaggca gaaacacaca cacatagaaa tgcagctgac 300
cttccaacag catggggcct gagggcgggtg acctccaccc aacagaaaat cctttataa 360
cttttgcactc cccaaaaaaac ctgactagaa atagcctact gttgacgggg gaggcttacc 420
aataacataa atagtcgatt tatgcatacg ttttatgcatt tcatgatata cttttgttgg 480
aatttttga tatttctaa acacagtt cgtctgtgaa tttttttaaa ttgttgcaac 540
tctcctaaaa tttttctaa tgtgttatt gaaaaaaatc caagtataag tggacttgc 600
cagttcaaac cagggttgtt caagggtcaa ctgtgt 636

-20-

SEQ ID NO:8

auggaaaacg aauuguucug cucgggcguc cuggugcauc cgcatggggu gcugucagcc 60
gcacacuguu uccagaacuc cuacaccauc gggcuggggcc ugcacagucu ugaggccgac 120
caagagccag ggagccagau gguggaggcc agccucuccg uacggcaccc agaguacaac 180
agacccuugc ucgcuaacga ccucaugcuc aucaaguugg acgaauccgu guccgagucu 240
gacaccaucc ggagcaucag cauugcuucg cagugccua ccgcggggaa cucuugccuc 300
guuuucuggcu ggggucugcu ggcgaacggc agaaugccua ccgugcugca gugcgugaac 360
gugucggugg ugucugagga ggucugcagu aagcucuaug acccgugua ccaccccagc 420
auguucugcg ccggcgagg gcaagaccag aaggacuccu gcaacgguga cucugggggg 480
ccccugaucu gcaacggua cuugcagggc cuugugucuu ucggaaaagc cccguguggc 540
caaguuggcg ugccaggugu cuacaccaac cucugcaaa ucacugagug gauagagaaa 600
accguccagg ccaguuaa 618

SEQ ID NO:9

auggaaaacg aauuguucug cucgggcguc cuggugcauc cgcatggggu gcugucagcc 60
gcacacuguu uccagaacuc cuacaccauc gggcuggggcc ugcacagucu ugaggccgac 120
caagagccag ggagccagau gguggaggcc agccucuccg uacggcaccc agaguacaac 180
agacccuugc ucgcuaacga ccucaugcuc aucaaguugg acgaauccgu guccgagucu 240
gacaccaucc ggagcaucag cauugcuucg cagugccua ccgcggggaa cucuugccuc 300
guuuucuggcu ggggucugcu ggcgaacggg ugacucuggg gggccugga ucugcaacgg 360
guacuuggcag ggccuugguc uuucggaaaa gccccgugug gccaaguugg cgugccaggu 420
gucuacacca accucugcaa auucacugag ugauagaga aaaccgucca ggccaguuaa 480

SEQ ID NO:10

auggaaaacg aauuguucug cucgggcguc cuggugcauc cgcatggggu gcugucagcc 60
gcacacuguu uccagaacuc cuacaccauc gggcuggggcc ugcacagucu ugaggccgac 120
caagagccag ggagccagau gguggaggcc agccucuccg uacggcaccc agaguacaac 180
agacccuugc ucgcuaacga ccucagcua ucaaguugga cgaauccgug uccgagucug 240
acaccauccg gagcaucagc auugcuucgc agugccuac cgcggggaac ucuugccucg 300

-21-

uuucuggcug gggucugcug gcgaacggug agcucacggg uggugugcug cccucuucaa 360
ggaggguccuc ugcccagucg cggggcuga cccagagcuc ugcgucccag gcagaaugcc 420
uaccgugcug cagugcguga acgugucggu ggugucugag gaggucugca guaagcucua 480
ugacccgcug uaccacccca gcauguucug cgccggcggg gggcaagacc agaaggacuc 540
cugcaacggu gacucugggg gggcccugau cugcaacggg uacuugcagg gccuuguguc 600
uuucggaaaa gccccguguu ggccaaguug gcgugccagg ugucuacacc aaccucugca 660
aauucacuga guggauagag aaaaccgucc aggccaguua a 701

SEQ ID NO:11

ggaaugagcc uggauccggg gagcccagag ggaagggcug ggaggcggga auctuugcuuc 60
ggaaggacuc agagaguccg acuugaaauc ucagcccagu gcugagucuc uagugaacua 120
agcuccuaca ccaucgggcu gggccugcac agucuugagg ccgaccaaga gccagggagc 180
cagaggugga ggcgcagccuc uccguacggc acccagagua caacagaccc uugcucgcua 240
acgaccucau gcucaucaag uuggacgaaau ccguguccga gucugacacc auccggagca 300
ucagcauugc uucgcagugc ccuaccgcgg ggaacucuuug ccucguuuucu ggcugggguc 360
ugcuggcgaa cgggaacuca cggugugug ucugcccucu ucaaggaggu ccucugccca 420
gucgcggggg cugacccaga gcucugcguc ccaggcagaa gccuacccug cugcagugcg 480
ugaacguguc gguggugucu gaggaggucu gcauguaagcu cuaugaccccg cuguaccacc 540
ccagcauguu cugcgccggc ggagggcaag accagaagga cuccugcaac ggugacucug 600
ggggggcccu gaucugcaac ggguacuugc agggccuugu gcuuuucgga aaagccccgu 660
guggccaagu ugugcugccca ggugucuaca ccaaccucug caaauucacu gaguggauag 720
agaaaaccgu ccaggccagu uaacucuggg gacugggaac ccaugaaauu gaccccccgg 780
uacaucuugc ggaagggaaauu caggaauauc ugauccccagc cccuccuccc 830

SEQ ID NO:12

ggaaugagcc uggauccggg gagcccagag ggaagggcgg gaggcggaa ucuugcuucg 60
gaaggacuca gagagcccug acuugaaauc ucagcccagu gcugagucuc uagugaacua 120
agcuccuaca ccacgggcug ggcgcugcaca gucugaggc cgaccaagag ccagggagcc 180
agauggugga ggcgcagccuc uccguacggc acccagagua caacagaccc uugcucgcua 240
acgaccucau gcucaucaag uuggacgaaau ccguguccga gucugacacc auccggagca 300

-22-

ucagcauugc uucgcagugc ccuaccgcgg ggaacucuuug ccucguuuucu ggcugggguc 360
 ugcuggcgaa cggcagaaug ccuaccgcgg ugcagugcgu gaacgugucg guggugucug 420
 aggaggucug caguaagc 438

SEQ ID NO:13

gcucugggag gaggacggaa ugagccugga uccggggagc ccagagggaa gggcuggggag 60
 gcgggaaucu ugcuucggaa ggacucagag agcccugacu ugaaaucuca gcccagugcu 120
 gagucucuag ugaacuaagc uccuacacca ucgggcuggg ccugcacagu cuugaggccg 180
 accaagagcc agggagccag augguggagg ccagccucuc cguacggcac ccagaguaca 240
 acagacccuu gcucgcuaac gaccucaugc caucaaguug gacgaauccg uguccgaguc 300
 ugacaccauc cggagcauca gcauugcuuc gcagugccu accgcggggaa acucuugccu 360
 cguuucuggc uggggucugc uggcgaacgg cagaauugccu accgugcugc agugcugaa 420
 cgugucggug gugucugagg aggucugcag uaagc 455

SEQ ID NO:14

accaccccaag cauguucugc gccggccggag agcaagacca gaaggacucc ugcaacguga 60
 gagaggggaa aggggagggc aggacuca gggaaaggug gagaaggggg agacagagac 120
 acacagggcc gcauggcgag augcagagau ggagagacac acagggagac agugacaacu 180
 agagagagaa acugagagaa acagggaaau aaacacagga auaaagagaa gcaaaggaag 240
 agagaaacag aaacagacau gggggaggca gaaacacaca cacauagaaa ugcagcugac 300
 cuuccaacag cauggggccu gagggcggug accuccaccc aacagaaaaau ccucuuauaa 360
 cuuuugacuc cccaaaaaac cugacuagaa auagccuacu guugacgggg gagccuuacc 420
 aauaacaauaa auagucgauu uaugcauacg uuuuaugcau ucaugauaua ccuuuguugg 480
 auuuuuuuuga uauuuucuaag cuacacaguu cgucugugaa uuuuuuuuaaa uuguugcaac 540
 ucuccuaaaa uuuuuucuaa uguguuuauu gaaaaaaaauc caaguaaagu ggacuugugc 600
 aguucaaacc aggguuguuc aagggucaac ugugu 635

SEQ ID NO:15

Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp
 Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu

-23-

Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val
Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu
Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser
Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly
Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Arg Met
Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu Glu Val
Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe Cys Ala
Gly Gly Gly Gln Asp Gln Lys Asp Ser Cys Asn Gly Asp Ser Gly Gly
Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe Gly Lys
Ala Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn Leu Cys
Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser

SEQ ID NO:16

Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp
Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu
Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val
Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu
Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser
Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly
Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly

SEQ ID NO:17

Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp
Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu
Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val
Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu
Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser
Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly
Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Glu Leu
Thr Gly Val Cys Leu Pro Ser Ser Arg Arg Ser Ser Ala Gln Ser Arg

-24-

Gly Leu Thr Gln Ser Ser Ala Ser Gln Ala Glu Cys Leu Pro Cys Cys
Ser Ala

SEQ ID NO:18

Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro
Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser
Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr
Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly
Glu Leu Thr Gly Val Cys Leu Pro Ser Ser Arg Arg Ser Ser Ala Gln
Ser Arg Gly Leu Thr Gln Ser Ser Ala Ser Gln Ala Glu Cys Leu Pro
Cys Cys Ser Ala

SEQ ID NO: 19

Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro
Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser
Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr
Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly
Arg Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu
Glu Val Cys Ser Lys

SEQ ID NO:20

Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro
Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser
Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr
Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly
Arg Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu
Glu Val Cys Ser Lys

-25-

SEQ ID NO:21

Ala Ile Ser Ser Gln Val Phe Trp Gly Val Lys Ser Tyr Lys Arg Ile
Phe Cys Trp Val Glu Val Thr Ala Leu Arg Pro His Ala Val Gly Arg
Ser Ala Ala Phe Leu Cys Val Cys Val Ser Ala Ser Pro Met Ser Val
Ser Val Ser Leu Phe Leu Cys Phe Ser Leu Phe Leu Cys Leu Phe Pro
Cys Phe Ser Gln Phe Leu Ser Leu Val Val Thr Val Ser Leu Cys Val
Ser Pro Ser Leu His Leu Ala Met Arg Pro Cys Val Ser Leu Ser Pro
Pro Ser Pro Pro Phe Pro Glu Ser Pro Ala Leu Pro Phe Pro Leu Ser
His Val Ala Gly Val Leu Leu Val Leu Leu Ser Ala Gly Ala Glu His
Ala Gly Val

1000 800 600 400 200 100 80 60 40 20 10 5 3 2 1

CLAIMS

What is claimed is:

1. A polynucleotide comprising the nucleotide sequence of SEQ ID NO:3, wherein the nucleotide sequence encodes an intracellular protein.
2. The polynucleotide of claim 1 wherein the intracellular protein has a predominantly nuclear localization in a cell.
3. A polynucleotide comprising the nucleotide sequence of SEQ ID NO:4, wherein the nucleotide sequence encodes an intracellular protein.
4. A polynucleotide comprising the nucleotide sequence of SEQ ID NO:7, wherein the nucleotide sequence encodes an intracellular protein.
5. The polynucleotide of any one of claim 1, 3, or 4 wherein the polynucleotide is expressed *in vivo* in a prostate cancer cell.
6. The polynucleotide of any one of claims 1, 3, or 4 wherein the expression of the polynucleotide is dependent on at least one of an androgen, a progesterone, an estrogen, and a glucocorticoid.
7. A polynucleotide having at least 90% identity to at least one of SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:7, wherein the polynucleotide encodes an intracellular protein.
8. A polynucleotide having at least 95% identity to at least one of SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:7, wherein the polynucleotide encodes an intracellular protein.
9. A polypeptide comprising the amino acid sequence of SEQ ID NO:10, wherein the amino acid sequence is expressed *in vivo* in a prostate cancer cell.
10. The polypeptide of claim 9 wherein the polypeptide has a predominantly nuclear localization in a cell.

11. A polypeptide comprising the amino acid sequence of SEQ ID NO:11, wherein the amino acid sequence is expressed *in vivo* in a prostate cancer cell.

12. A polypeptide comprising the amino acid sequence of SEQ ID NO:14, wherein the amino acid sequence is expressed *in vivo* in a prostate cancer cell.

13. A polypeptide having at least 90% homology to at least one of SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:14, wherein the polypeptide is an intracellular protein.

14. A polypeptide having at least 95% homology to at least one of SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:14, wherein the polypeptide is an intracellular protein.

15. A method of detecting a neoplastic cell, comprising:
correlating a predetermined quantity of an RNA comprising at least one of SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:21 in a cell containing system with a presence of a neoplastic cell, wherein the RNA encodes an intracellular polypeptide; and
detecting at least the predetermined quantity of the RNA in the system.

16. The method of claim 15 wherein the neoplastic cell is a prostate cancer cell.

17. The method of claim 15 wherein the system is a mammal.

18. The method of claim 15 wherein the step of detecting includes hybridization of a probe to at least one of the SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:21.

19. The method of claim 18 wherein the probe carries a label that is detected by a process selected from the group consisting of fluorescence detection, luminescence detection, scintigraphy, autoradiography, and formation of a dye.

20. The method of claim 18 wherein at least one nucleotide is enzymatically coupled to the probe while the probe is hybridized to the at least one of the SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:21.

21. A method of detecting a neoplastic cell, comprising:
correlating a predetermined quantity of an intracellular polypeptide comprising at least one of SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:14 in a cell containing system with a presence of a neoplastic cell; and

detecting at least the predetermined quantity of the intracellular polypeptide in the system.

22. The method of claim 21 wherein the neoplastic cell is a prostate cancer cell or a breast cancer cell.
23. The method of claim 21 wherein the system is a mammal.
24. The method of claim 21 wherein the step of detecting includes specifically binding of a probe to the polypeptide.
25. The method of claim 24 wherein the probe is selected from the group consisting of an antibody, an antibody fragment, a natural ligand of the polypeptide, and a synthetic ligand of the polypeptide.
26. The method of claim 24 wherein the probe carries a label that is detected by a process selected from the group consisting of fluorescence detection, luminescence detection, scintigraphy, autoradiography, and formation of a dye.
27. A method of identifying differentially expressed genes in a target tissue, comprising:
providing a target tissue-specific cDNA library having a plurality of tissue-specific genes, wherein the tissue-specific genes are obtained by suppression subtractive hybridization;
immobilizing a predetermined quantity of tissue-specific genes on a solid phase to form a tissue-specific cDNA array;
hybridizing a first nucleic acid preparation to a first tissue-specific cDNA array to create a first hybridization pattern, wherein the first preparation is prepared from the target tissue without previously exposing the target tissue to a compound;
hybridizing a second nucleic acid preparation to a second tissue-specific cDNA array to create a second hybridization pattern, wherein the second preparation is prepared from the target tissue after previously exposing the target tissue to a compound; and
comparing the first and the second hybridization pattern to identify differentially expressed genes.

28. The method of claim 27 wherein the target tissue comprises prostate tissue.
29. The method of claim 28 wherein the prostate tissue comprises prostate cancer cells.
30. The method of claim 27 wherein the solid phase comprises a membrane.
31. The method of claim 27 wherein the compound comprises a hormone.
32. The method of claim 27 wherein at least one of the first and second nucleic acid preparations is radiolabeled and wherein the step of comparing comprises phosphorimaging.




Figure 1A

C:\USERS\HOMER\DESKTOP\1A.DOC

	20	40	60	80	100		
SEQ ID NO:8 :	MENELFCSGVLVHPQWVLSAAHCFQNSTTYIGLGLHSLEADQEPGSQ	VEASLSVRHPEYNRPLANDLMLIKLDEVSESDTIRSISIASQCPTAGNSCLVSGWGLL	ANG			110	
SEQ ID NO:9 :	MENELFCSGVLVHPQWVLSAAHCFQNSTTYIGLGLHSLEADQEPGSQ	VEASLSVRHPEYNRPLANDLMLIKLDEVSESDTIRSISIASQCPTAGNSCLVSGWGLL	ANG			110	
SEQ ID NO:10 :	MENELFCSGVLVHPQWVLSAAHCFQNSTTYIGLGLHSLEADQEPGSQ	VEASLSVRHPEYNRPLANDLMLIKLDEVSESDTIRSISIASQCPTAGNSCLVSGWGLL	ANG			110	
SEQ ID NO:11 :	-----	-----	-----	-----	-----	110	
SEQ ID NO:12 :	-----	-----	-----	-----	-----	64	
SEQ ID NO:13 :	-----	-----	-----	-----	-----	64	
	120	140	160	180	200		
SEQ ID NO:8 :	RMP-----	TVLQCVNVSVVSEEV-----	SKLYDPLYHPSMFCA	AGGGQDQK	DSCNGDGGPLIC	NGYLQGLVSGKAPCGQVGVIGVYTNLCKPTEWIEKTVQAS	: 205
SEQ ID NO:9 :	-----	-----	-----	-----	-----	-----	-----
SEQ ID NO:10 :	ELTGVLCLPSSRRSSAOSRLGTOSSA5QAE	SLPCCSA-----	-----	-----	-----	-----	146
SEQ ID NO:11 :	ELTGVLCLPSSRRSSAOSRLGTOSSA5QAE	SLPCCSA-----	-----	-----	-----	-----	100
SEQ ID NO:12 :	RMP-----	TVLQCVNVSVVSEEV-----	SK-----	-----	-----	-----	85
SEQ ID NO:13 :	RMP-----	TVLQCVNVSVVSEEV-----	SK-----	-----	-----	-----	85

Figure 1B




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

SEQUENCE LISTING

<110> Saatcioglu, Fahri

<120> Differentially Expressed Genes in Prostate Cancer

<130> Sequences for 586.02-PCT

<140>

<141>

<150> 60/135,325

<151> 1999-05-20

<150> 60/135,333

<151> 1999-05-20

<160> 21

<170> PatentIn Ver. 2.0

<210> 1

<211> 618

<212> DNA

<213> Homo sapiens

<400> 1

atggaaaaacg aattgttctg ctggggcgtc ctgggtgcattc cgccgtgggt gctgtcagcc 60
gcacactgtt tccagaactc ctacaccatc gggctgggcc tgcacagtct tgaggccgac 120
caagagccag ggagccagat ggtggaggcc agcctctccg tacggcaccc agagtacaac 180
agacccttgc tgcgttaacga cctcatgctc atcaagttgg acgaatccgt gtccgagtct 240
gacaccatcc ggagcatcag cattgcttgc cagtgcctta ccgcggggaa ctcttgctc 300
gtttctggct ggggtctgtt ggcgaacggc agaatgccta ccgtgctgca gtgcgtgaac 360
gtgtcggtgg tgcgttgagga ggtctgcagt aagctctatg acccgctgtta ccaccccagc 420
atgttctgctc ccggcgagg gcaagaccag aaggactctt gcaacgggtga ctctgggggg 480
cccctgatct gcaacgggtta cttgcagggc cttgtgtctt tcggaaaagc cccgtgtggc 540
caagttggcg tgccaggtgt ctacaccaac ctctgcaaattt tcactgagtg gatagagaaa 600
accgtccagg ccagttaa 618

<210> 2

<211> 481

<212> DNA

<213> Homo sapiens

<400> 2

atggaaaaacg aattgttctg ctggggcgtc ctgggtgcattc cgccgtgggt gctgtcagcc 60
gcacactgtt tccagaactc ctacaccatc gggctgggcc tgcacagtct tgaggccgac 120
caagagccag ggagccagat ggtggaggcc agcctctccg tacggcaccc agagtacaac 180

agacccttgc tcgctaacga cctcatgctc atcaagttgg acgaatccgt gtccgagtct 240
 gacaccatcc ggagcatcag cattgcttcg cagtgcctta ccgcggggaa ctcttgccctc 300
 gtttctggct ggggtctgct ggcaacggg tgactctggg gggccctga tctgcaacgg 360
 gtacttgcag ggccttgtgt ctttcggaaa agccccgtgt ggccaagttg gcgtgccagg 420
 tgtctacacc aacctctgca aattcactga gtggatagag aaaaccgtcc aggccagtta 480
 a 481

<210> 3
 <211> 702
 <212> DNA
 <213> Homo sapiens

<400> 3
 atggaaaacg aattgttctg ctcgggcgtc ctgggtgcattc cgcaagtgggt gctgtcagcc 60
 gcacactgtt tccagaactc ctacaccatc gggctgggccc tgacatgtct tgaggccgac 120
 caagagccag ggagccagat ggtggaggcc agcctctccg tacggcaccc agagtacaac 180
 agacccttgc tcgctaacga cctcatgctc atcaagttgg acgaatccgt gtccgagtct 240
 gacaccatcc ggagcatcag cattgcttcg cagtgcctta ccgcggggaa ctcttgccctc 300
 gtttctggct ggggtctgct ggcaacggg gagctcacgg gtgtgtgtct gccctttca 360
 aggaggtcct ctgcccagtc gcgggggctg accccagagct ctgcgtccca ggcagaatgc 420
 ctaccgtgt gcagtgcgtg aacgtgtcgg tgggtgtctga ggaggtctgc agtaagctct 480
 atgaccgcgt gtaccacccc agcatgttct gcgcggcgg agggcaagac cagaaggact 540
 cctgcaacgg tgactctggg gggccctga tctgcaacgg gtacttgcag ggccttgg 600
 ctttcggaaa agccccgtgt tggccaagtt ggcgtgccag gtgtctacac caacctctgc 660
 aaattcactg agtggataga gaaaaccgtc cagggcagtt aa 702

<210> 4
 <211> 834
 <212> DNA
 <213> Homo sapiens

<400> 4
 ggaatgagcc tggatccggg gagcccagag ggaaggcgtg ggaggcggga atcttgcttc 60
 ggaaggactc agagagtctt gacttgaat ctcagcccag tgctgagttct ctatgtaaact 120
 aagctcttac accatgggc tgggcctgca cagtcttgcg gccgaccaag agccaggagg 180
 ccagatgggt gaggccagcc tctccgtacg gcacccagag tacaacagac cttgtctcgc 240
 taacgacctc atgctcatca agttggacga atccgtgtcc gagtctgaca ccatccggag 300
 catcagcatt gcttcgcgtt gcccattaccgc gggaaactct tgctcggtt ctggctgggg 360
 tctgctggcg aacggtaac tcacgggtgt gtgtctgccc tcttcaagga ggtcctctgc 420
 ccagtcgcgg gggctgaccc agagctctgc'gtcccaaggca gaatgcctac cgtgtgcag 480
 tgcgtgaacg tgcgtgtgt gtctgaggag gtctgcgtt agctctatga cccgctgtac 540
 caccggcata tggatccggc cggcggaggca agaaccaga aggactcctg caacggtgac 600
 tctggggggc ccctgatctg caacgggtac ttgcaggccc ttgtgtcttt cggaaaagcc 660
 ccgtgtggcc aagttggcgt gccaggtgtc tacaccaacc tctgcaatt cactgagtgg 720
 atagagaaaaa ccgtccaggc cagttactc tgggactgg gaaccatga aattgacccc 780
 caaatacata ctgcggaaagg aattcaggaa tatctgatcc cagccctcc tccc 834

<210> 5

<211> 440
 <212> DNA
 <213> Homo sapiens

<400> 5
 ggaatgagcc tggatccggg gagcccagag ggaaggcgtg ggaggcggga atcttgcttc 60
 ggaaggactc agagagccct gacttgaaat ctcagcccgag tgctgagttct ctagtgaact 120
 aagctcctac accatcgggc tggcctgca cagtctttag gcccaccaag agccaggag 180
 ccagatggtg gaggccagcc tctccgtacg gcacccagag tacaacagac cttgtctcgc 240
 taacgacctc atgctcatca agttggacga atccgtgtcc gagttctgaca ccattccggag 300
 catcagcatt gtttcgcagt gcccattaccgc gggaaactct tgcctcggtt ctggctgggg 360
 tctgctggcg aacggcagaa tgcctaccgt gctgcagtgc gtgaacgtgt cggtgggtgc 420
 tgaggaggc tgcagtaagc 440

<210> 6
 <211> 457
 <212> DNA
 <213> Homo sapiens

<400> 6
 ggctctggga ggaggacgga atgagcctgg atccggggag cccagaggga agggctggga 60
 ggccggaaatc ttgctcggaa aggactcaga gagccctgac ttgaaatctc agcccaagtgc 120
 ttagtctcta gtgaactaag ctcctacacc atcgggctgg gcctgcacag tcttggggcc 180
 gaccaagagc caggagcca gatgggtggag gccagccctc cctgtacggca cccagagtac 240
 aacagacccct tgctcgtcaa cgacctcatg ctcatcaagt tggacgaatc cgtgtccggag 300
 tctgacacca tccggagcat cagcattgtc tgcgtgtcc ctaccgcggg gaactcttgc 360
 ctctttctg gctgggtct gctggcgaac ggcagaatgc ctaccgtgtc gcagtgcgtg 420
 aacgtgtcgg tgggtctga ggaggtctgc agtaagc 457

<210> 7
 <211> 636
 <212> DNA
 <213> Homo sapiens

<400> 7
 accaccccaag catgttctgc gccggcggag agcaagacca gaaggactcc tgcaacgtga 60
 gagaggggaa aggggagggc aggcaactca gggaaagggtg gagaaggggg agacagagac 120
 acacaggggcc gcatggcgag atgcagagat ggagagacac acagggagac agtgacaact 180
 agagagagaa actgagagaa acagggaaat aaacacagga ataaagagaa gcaaaggaag 240
 agagaaacag aaacagacat gggggaggca gaaacacaca cacatagaaa tgcagctgac 300
 cttccaacag catggggcct gagggcggtg acctccaccc aacagaaaat cctctataa 360
 cttttgactc cccaaaaaaac ctgactagaa atagcctact gttgacgggg gagccttacc 420
 aataacataa atagtcgatt tatgcatacg ttttatgcat tcatgtatata ctttttttgg 480
 aattttttga tattttcaag ctacacagtt cgtctgtgaa tttttttaaa ttgttgcac 540
 tctcctaaaa ttttttctaa ttttttttatt gaaaaaaatc caagtataag tggacttgc 600
 cagttcaaacc cagggttggta caagggtcaa ctgtgt 636

<210> 8

<211> 618
 <212> RNA
 <213> Homo sapiens

<400> 8

auggaaaaacg aauuguucug cucgggcguc cuggugcauc cgcauggggu gcugucagcc 60
 gcacacuguu uccagaacuc cuacaccauc gggcugggcc ugcacagucu ugaggccgac 120
 caagagccag ggagccagau gguggaggcc agccucuccg uacggcaccc agaguacaac 180
 agacccuugc ucgcuacga ccucaugcuc aucaaguugg acgaaucggu guccgagucu 240
 gacaccaucc ggagcaucag cauugcuucg cagugccua ccgcggggaa cucuugccuc 300
 guuucuggcu gggucugcu ggcgaacggc agaaugccua ccgugcugca gugcgugaac 360
 gugucggugg ugcugagga ggucugcagu aagcucuaug acccgugua ccaccccg 420
 auguucugcg ccggcgagg gcaagaccag aaggacuccu gcaacgguga cucugggggg 480
 cccugaucu gcaacggua cuugcaggcg cuugugucuu ucggaaaagc cccuguggc 540
 caaguuggcg ugccaggugu cuacaccaac cucugcaaau ucacugagug gauagagaaa 600
 accguccagg ccaguuaa 618

<210> 9
 <211> 480
 <212> RNA
 <213> Homo sapiens

<400> 9

auggaaaaacg aauuguucug cucgggcguc cuggugcauc cgcauggggu gcugucagcc 60
 gcacacuguu uccagaacuc cuacaccauc gggcugggcc ugcacagucu ugaggccgac 120
 caagagccag ggagccagau gguggaggcc agccucuccg uacggcaccc agaguacaac 180
 agacccuugc ucgcuacga ccucaugcuc aucaaguugg acgaaucggu guccgagucu 240
 gacaccaucc ggagcaucag cauugcuucg cagugccua ccgcggggaa cucuugccuc 300
 guuucuggcu gggucugcu ggcgaacggg ugacucuggg gggcccuuga ucugcaacgg 360
 guacuugcag ggccuugguc uuucggaaaa gccccgugug gccaaguugg cgugccaggu 420
 gucuacacca accucugcaa auucacugag uggauagaga aaacccgucca ggcaguuuaa 480

<210> 10
 <211> 701
 <212> RNA
 <213> Homo sapiens

<400> 10

auggaaaaacg aauuguucug cucgggcguc cuggugcauc cgcauggggu gcugucagcc 60
 gcacacuguu uccagaacuc cuacaccauc gggcugggcc ugcacagucu ugaggccgac 120
 caagagccag ggagccagau gguggaggcc agccucuccg uacggcaccc agaguacaac 180
 agacccuugc ucgcuacga ccucaugcuc ucaaguugg cgaaucggug uccgagucug 240
 acaccauccc gagcaucagc auugcuucgc agugccuaac ccgcggggaa ucuugccucg 300
 uuucuggcgug gggucugcug gcaacggug agcucacggg ugugugucug cccucuucaa 360
 ggagguccuc ugcccagucg cggggcuga cccagagcuc ugcguccag gcagaauugcc 420
 uaccgugcug cagugcugua acgugucggu ggugucugag gaggucugca guaagcucua 480
 ugacccgug uaccacccca gcauguucug ccgcggcgga gggcaagacc agaaggacuc 540
 cugcaacggu gacucugggg gggccuugau cugcaacggg uacuugcagg gccuuguguc 600

uuucggaaaa gccccguguu ggccaaguug gcgugccagg ugucuacacc aaccucugca 660
 aauucacuga guggauagag aaaaccgucc aggccaguua a 701

<210> 11
 <211> 830
 <212> RNA
 <213> Homo sapiens

<400> 11
 gaaaugagcc uggauccggg gagcccagag ggaagggcug ggaggcgaa aucuugcuuc 60
 ggaaggacuc agagaguccg acuugaaauc ucagcccagu gcugagucuc uagugaacua 120
 agcuccuaca ccaucggcu gggccugcac agucuugagg cccaccaaga gccagggagc 180
 cagaggugga ggccagccuc uccguacggc acccagagua caacagaccc uugcucgcua 240
 acgaccucau gcucaucaag uuggacgaaau ccguguccga gucugacacc auccggagca 300
 ucagcauugc uucgcagugc ccuaccggcg ggaacucuug ccucguuuu 360
 ugcuggcgaa cgggaacuca cgggugugug ucugcccuc ucaaggaggu ccucugccca 420
 gugcgggggg cugacccaga gcucugcguc ccaggcagaa gccuaccgug cugcagugcg 480
 ugaacguguc gguggugucu gaggaggucu gcaguaagcu cuaugaccc cuguaccacc 540
 ccagcauguu cugcgccggc ggagggcaag accagaagga cuccugcaac ggugacucug 600
 gggggccccc gauugcaac ggguacuugc agggccuugu gcuuuucgga aaagccccgu 660
 guggccaagu ugugcugcca ggugucuaca ccaaccucug caaaucacu gaguggauag 720
 agaaaaccgu ccaggccagu uaacucuggg gacugggAAC ccaugaaaa gaccccaaaa 780
 uacaucuugc ggaaggaaau caggaauauc ugaucccagc cccuccuucc 830

<210> 12
 <211> 438
 <212> RNA
 <213> Homo sapiens

<400> 12
 gaaaugagcc uggauccggg gagcccagag ggaagggcg gaggcgaa ucuugcuucg 60
 ggaaggacuca gagagccug acuugaaauc ucagcccagu gcugagucuc uagugaacua 120
 agcuccuaca ccacggcgug gggcugcaca gcuuugaggc cccaccaaga ccaggagcc 180
 agauggugga ggccagccuc uccguacggc acccagagua caacagaccc uugcucgcua 240
 acgaccucau gcucaucaag uuggacgaaau ccguguccga gucugacacc auccggagca 300
 ucagcauugc uucgcagugc ccuaccggcg ggaacucuug ccucguuuu 360
 ugcuggcgaa cggcagaaug ccuaccgugc ugcagugcgu gaacgugucg guggugucug 420
 aggaggucug caguaagc 438

<210> 13
 <211> 455
 <212> RNA
 <213> Homo sapiens

<400> 13
 gcucuggggag gaggacggaa ugagccugga uccggggagc ccagagggaa gggcuggggag 60
 gcgggaaucu ugcuucggaa ggacucagag agccugacu ugaaaaucuca gcccagugcu 120
 gagucucuag ugaacuaagc uccuacacca ucgggcuggg ccugcacagu cuugaggccg 180

accaagagcc agggagccag augguggagg ccagccucuc cguacggcac ccagaguaca 240
 acagacccuu gcucgcuaac gaccuaugc caucaaguug gacgaaucgg uguccgaguc 300
 ugacaccauc cggagcauca gcauugcuuc gcagugccu accgcgggaa acucuugccu 360
 cguuucuggc ugugcgaacgg cagaauugccu accgugcugc agugcugaa 420
 cgugucggug gugucugagg aggucugcag uaagc 455

<210> 14
 <211> 635
 <212> RNA
 <213> Homo sapiens

<400> 14
 accaccccaag cauguucugc gccggcgagg agcaagacca gaaggacucc ugcaacguga 60
 gagaggggaa aggggagggc aggcgacuca gggaaaggug gagaaggggg agacagagac 120
 acacagggcc gcauggcgag augcagagau ggagagacac acagggagac agugacaacu 180
 agagagagaa acugagagaa acaggaaau aaacacagga auaaagagaa gcaaaggaag 240
 agagaaacag aaacagacau gggggaggca gaaacacaca cacauagaaa ugcagcugac 300
 cuuccaacag cauggggccu gagggcgug accuccaccc aacagaaaaa ccucuuauaa 360
 cuuugacuc cccaaaaac cugacuagaa auagccuacu guugacgggg gagccuuacc 420
 aauaacauaa auagucgauu uaugcauacg uuuuauugcau ucaugauaua ccuuguugg 480
 aauuuuuuga uauuucuaag cuacacaguu cgucugugaa uuuuuuuuuaa uuguugcaac 540
 cuccuaaaaa uuuuuucuaa uguguuuauu gaaaaaaauc caaguaaagu ggacuugugc 600
 aguucaaacc aggguuguuc aaggguacaac ugugu 635

<210> 15
 <211> 205
 <212> PRT
 <213> Homo sapiens

<400> 15
 Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp
 1 5 10 15

Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu.
 20 25 30

Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val
 35 40 45

Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu
 50 55 60

Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser
 65 70 75 80

Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly
 85 90 95

Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Arg Met
100 105 110

Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu Glu Val
115 120 125

Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe Cys Ala
130 135 140

Gly Gly Gly Gln Asp Gln Lys Asp Ser Cys Asn Gly Asp Ser Gly Gly
145 150 155 160

Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe Gly Lys
165 170 175

Ala Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn Leu Cys
180 185 190

Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser
195 200 205

<210> 16

<211> 110

<212> PRT

<213> Homo sapiens

<400> 16

Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp
1 5 10 15

Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu
20 25 30

Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val
35 40 45

Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu
50 55 60

Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser
65 70 75 80

Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly
85 90 95

Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly
100 105 110

<210> 17
<211> 146
<212> PRT
<213> Homo sapiens

<400> 17
Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp
1 5 10 15

Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu
20 25 30

Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val
35 40 45

Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu
50 55 60

Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser
65 70 75 80

Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly
85 90 95

Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Glu Leu
100 105 110

Thr Gly Val Cys Leu Pro Ser Ser Arg Arg Ser Ser Ala Gln Ser Arg
115 120 125

Gly Leu Thr Gln Ser Ser Ala Ser Gln Ala Glu Cys Leu Pro Cys Cys
130 135 140

Ser Ala
145

<210> 18
<211> 100
<212> PRT
<213> Homo sapiens

<400> 18
Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro
1 5 10 15

Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser
 20 25 30

Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr
 35 40 45

Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly
 50 55 60

Glu Leu Thr Gly Val Cys Leu Pro Ser Ser Arg Arg Ser Ser Ala Gln
 65 70 75 80

Ser Arg Gly Leu Thr Gln Ser Ser Ala Ser Gln Ala Glu Cys Leu Pro
 85 90 95

Cys Cys Ser Ala
 100

<210> 19

<211> 85

<212> PRT

<213> Homo sapiens

<400> 19

Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro
 1 5 10 15

Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser
 20 25 30

Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr
 35 40 45

Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly
 50 55 60

Arg Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu
 65 70 75 80

Glu Val Cys Ser Lys
 85

<210> 20

<211> 85

<212> PRT

<213> Homo sapiens

<400> 20

Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro
1 5 10 15

Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser
20 25 30

Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr
35 40 45

Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly
50 55 60

Arg Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu
65 70 75 80

Glu Val Cys Ser Lys
85

<210> 21

<211> 131

<212> PRT

<213> Homo sapiens

<400> 21

Ala Ile Ser Ser Gln Val Phe Trp Gly Val Lys Ser Tyr Lys Arg Ile
1 5 10 15

Phe Cys Trp Val Glu Val Thr Ala Leu Arg Pro His Ala Val Gly Arg
20 25 30

Ser Ala Ala Phe Leu Cys Val Cys Val Ser Ala Ser Pro Met Ser Val
35 40 45

Ser Val Ser Leu Phe Leu Cys Phe Ser Leu Phe Leu Cys Leu Phe Pro
50 55 60

Cys Phe Ser Gln Phe Leu Ser Leu Val Val Thr Val Ser Leu Cys Val
65 70 75 80

Ser Pro Ser Leu His Leu Ala Met Arg Pro Cys Val Ser Leu Ser Pro
85 90 95

Pro Ser Pro Pro Phe Pro Glu Ser Pro Ala Leu Pro Phe Pro Leu Ser
100 105 110

His Val Ala Gly Val Leu Leu Val Leu Leu Ser Ala Gly Ala Glu His
115 120 125

Ala Gly Val
130

Practitioner's Docket No. 586.02-US1

PATENT

COMBINED DECLARATION AND POWER OF ATTORNEY**(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL,
CONTINUATION, OR C-I-P)**

As a below named inventor, I hereby declare that:

TYPE OF DECLARATION

This declaration is for a national stage of PCT application.

INVENTORSHIP IDENTIFICATION

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am the original, first and sole inventor of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

DIFFERENTIALLY EXPRESSED GENES IN PROSTATE CANCER

SPECIFICATION IDENTIFICATION

The specification was described and claimed in PCT International Application No. PCT/IB00/00673 filed on May 19, 2000.

ACKNOWLEDGMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, Section 1.56, and which is material to the examination of this application, namely, information where there is a substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent.

PRIORITY CLAIM (35 U.S.C. Section 119(a)-(d))

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international

(Declaration and Power of Attorney—page 1 of 3)

application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Such applications have been filed as follows.

CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)
(35 U.S.C. Section 119(e))

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

PROVISIONAL APPLICATION NUMBER	FILING DATE
60/135,325	May 20, 1999
60/135,333	May 20, 1999

POWER OF ATTORNEY

I hereby appoint the following practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

APPOINTED PRACTITIONER(S)	REGISTRATION NUMBER(S)
Robert D. Fish	<u>33880</u>
David J. Zoetewey	<u>45258</u>
Sandra P. Thompson	<u>46264</u>
Martin Fessenmaier	<u>46697</u>
Bruce Fertel	<u>41742</u>

(S)

I hereby appoint the practitioner(s) associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO

Robert D. Fish
1440 N Harbor Blvd.
Suite 706
Fullerton, CA 92835
USA

Customer Number 24392

DIRECT TELEPHONE CALLS TO:

Robert D. Fish
(714) 449-2337

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE(S)

1-00
Fahri SAATCIOLLU
Inventor's signature
Date 8 Jan 2001


Country of Citizenship Turkey

Residence Frognerstuveien 40 D, 0776 Oslo, Norway

Post Office Address University of Oslo
Biotechnology Center of Oslo
PO Box 1125
Gaustadallen 21
N-Oslo N-1317 Blindern
NORWAY

N0Y

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies were found during scanning:

Page(s) _____ of _____ were not present
for scanning. (Document title)

Page(s) _____ of _____ were not present
for scanning. (Document title)



Scanned copy is best available.

Drawing.